249 related articles for article (PubMed ID: 17043628)
1. Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy.
Panigone S; Nunn AD
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):310-21. PubMed ID: 17043628
[TBL] [Abstract][Full Text] [Related]
2. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update.
Smith CJ; Volkert WA; Hoffman TJ
Nucl Med Biol; 2003 Nov; 30(8):861-8. PubMed ID: 14698790
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
Giblin MF; Sieckman GL; Shelton TD; Hoffman TJ; Forte LR; Volkert WA
Nucl Med Biol; 2006 May; 33(4):481-8. PubMed ID: 16720239
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
Zhang H; Chen J; Waldherr C; Hinni K; Waser B; Reubi JC; Maecke HR
Cancer Res; 2004 Sep; 64(18):6707-15. PubMed ID: 15374988
[TBL] [Abstract][Full Text] [Related]
5. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
de Visser M; Verwijnen SM; de Jong M
Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes.
Smith CJ; Volkert WA; Hoffman TJ
Nucl Med Biol; 2005 Oct; 32(7):733-40. PubMed ID: 16243649
[TBL] [Abstract][Full Text] [Related]
7. Radiopeptide imaging and therapy in Europe.
Ambrosini V; Fani M; Fanti S; Forrer F; Maecke HR
J Nucl Med; 2011 Dec; 52 Suppl 2():42S-55S. PubMed ID: 22144555
[TBL] [Abstract][Full Text] [Related]
8. In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice.
Marsouvanidis PJ; Melis M; de Blois E; Breeman WA; Krenning EP; Maina T; Nock BA; de Jong M
Cancer Biother Radiopharm; 2014 Nov; 29(9):359-67. PubMed ID: 25286347
[TBL] [Abstract][Full Text] [Related]
9. Bombesin receptor antagonists may be preferable to agonists for tumor targeting.
Cescato R; Maina T; Nock B; Nikolopoulou A; Charalambidis D; Piccand V; Reubi JC
J Nucl Med; 2008 Feb; 49(2):318-26. PubMed ID: 18199616
[TBL] [Abstract][Full Text] [Related]
10. Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging?
Van de Wiele C; Dumont F; van Belle S; Slegers G; Peers SH; Dierckx RA
Nucl Med Commun; 2001 Jan; 22(1):5-15. PubMed ID: 11233552
[TBL] [Abstract][Full Text] [Related]
11. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells.
Hoffman TJ; Gali H; Smith CJ; Sieckman GL; Hayes DL; Owen NK; Volkert WA
J Nucl Med; 2003 May; 44(5):823-31. PubMed ID: 12732685
[TBL] [Abstract][Full Text] [Related]
12. Gastrin-releasing peptide (GRP) analogues for cancer imaging.
Varvarigou A; Bouziotis P; Zikos C; Scopinaro F; De Vincentis G
Cancer Biother Radiopharm; 2004 Apr; 19(2):219-29. PubMed ID: 15186603
[TBL] [Abstract][Full Text] [Related]
13. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors.
García Garayoa E; Schweinsberg C; Maes V; Rüegg D; Blanc A; Bläuenstein P; Tourwé DA; Beck-Sickinger AG; Schubiger PA
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):42-50. PubMed ID: 17372572
[TBL] [Abstract][Full Text] [Related]
14. Candidates for peptide receptor radiotherapy today and in the future.
Reubi JC; Mäcke HR; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():67S-75S. PubMed ID: 15653654
[TBL] [Abstract][Full Text] [Related]
15. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
[TBL] [Abstract][Full Text] [Related]
16. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin.
Dumont RA; Tamma M; Braun F; Borkowski S; Reubi JC; Maecke H; Weber WA; Mansi R
J Nucl Med; 2013 May; 54(5):762-9. PubMed ID: 23492884
[TBL] [Abstract][Full Text] [Related]
17. Development of a new bombesin analog radiolabeled with lutetium-177: in vivo evaluation of the biological properties in Balb-C mice.
Pujatti PB; Santos JS; Massicano AV; Mengatti J; De Araújo EB
Cell Mol Biol (Noisy-le-grand); 2010 May; 56(2):18-24. PubMed ID: 20525454
[TBL] [Abstract][Full Text] [Related]
18. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
19. Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy.
Reynolds TS; Bandari RP; Jiang Z; Smith CJ
Curr Radiopharm; 2016; 9(1):33-43. PubMed ID: 25771366
[TBL] [Abstract][Full Text] [Related]
20. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
Lantry LE; Cappelletti E; Maddalena ME; Fox JS; Feng W; Chen J; Thomas R; Eaton SM; Bogdan NJ; Arunachalam T; Reubi JC; Raju N; Metcalfe EC; Lattuada L; Linder KE; Swenson RE; Tweedle MF; Nunn AD
J Nucl Med; 2006 Jul; 47(7):1144-52. PubMed ID: 16818949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]